📰 Scott Eells Bloomberg News
Page 5 - Scott Eells Bloomberg News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Scott Eells Bloomberg. Real-time updates on events, politics, business and more.
May 31, 2021
Ariel Investments CEO John Rogers, TIAA CEO Thasunda Duckett, and former American Express CEO Kenneth Chenault reflect on what the Tulsa events a century ago has meant to them.
May 5, 2021
Sheryl Sandberg’s Fiancé Tom Bernthal Honors Her Late Husband Dave Goldberg, Whom He Knew People 3 hrs ago © Provided by People Tom Bernthal Sheryl Sandberg and Tom Bernthal Sheryl Sandberg and her inner circle — including fiancé Tom Bernthal — are making sure her late husbands spirit lives on by awarding a select few deserving high school students a special scholarship. The Facebook COO, 51, announced this week the 2021 recipients of the Dave Goldberg Scholarship, a program establ...
January 29, 2021
J&J Vaccine Provides Strong Shield Against Severe Covid Bloomberg 1/29/2021 Riley Griffin and Robert Langreth © Photographer: Scott Eells/Bloomberg The Johnson & Johnson logo is arranged for a photograph in New York, U.S. (Bloomberg) -- Johnson & Johnson’s one-shot vaccine generated strong protection against Covid-19 in a large, late-stage trial, raising hopes that it can rapidly reshape a stumbling immunization campaign. Popular Searches In a study of more than 43,000 pe...
January 15, 2021
David Cohen: Biden taps former CIA deputy director to return to role CNN 1/15/2021 By Alex Marquardt and Veronica Stracqualursi, CNN © Scott Eells/Bloomberg/Getty Images David Cohen, undersecretary for terrorism and financial intelligence at the U.S. Treasury, speaks during an interview in New York, U.S., on Tuesday, March 18, 2014. Virtual currencies will benefit from government oversight that lends credibility to the market, according to the U.S. Treasury Departments top ...
January 14, 2021
New data on early-stage trials of Johnson & Johnson’s Covid-19 vaccine are giving experts increased confidence that the vaccine will work as they await results of a large Phase 3 trial expected in the coming weeks. The trial data, published Wednesday by the New England Journal of Medicine, offered an expanded and updated account of a paper posted weeks ago on a so-called preprint server. The paper showed that 90% or more of participants developed neutralizing antibodies against the vi...